Skip to Content
207

Celgene

  • Previous Rank224
  • Revenues ($M)$15,281.0
  • Revenue Percent Change17.5%
  • Profits ($M)$4,046.0
  • Profits Percent Change37.6%
  • Assets ($M)$35,480.0
  • Employees8,852

The biopharmaceutical company is the maker of Thalomid and various other drugs that treat multiple myeloma, inflammatory diseases, and various forms of cancer.

Fortune Data StoreLooking for leads, investment insights, or competitive intelligence?Get Premium Access

Company Info

CEO
Mark J. Alles
CEO Title
Chairman & Chief Executive Officer
Sector
Health Care
Industry
Pharmaceuticals
HQ Location
Summit, N.J.
Websitehttp://www.celgene.com
Years on Fortune 500 List8
Employees8,852

Key Financials (Last Fiscal Year)

$ millions% change
Revenues ($M)$15,281.017.5%
Profits ($M)$4,046.037.6%
Assets ($M)$35,480.0-
Total Stockholder Equity ($M)$6,161.0-

Profit Ratios

Profit as % of Revenues26.5%
Profits as % of Assets11.4%
Profits as % of Stockholder Equity65.7%

Earnings Per Share (Last Fiscal Year)

Earnings Per Share ($)5.51
EPS % Change (from 2017)51.4%
EPS % Change (5 year annual rate)26.7%
EPS % Change (10 year annual rate)-

Total Return

Total Return to Investors (2018)-38.6%
Total Return to Investors (5 year, annualized)-5.4%
Total Return to Investors (10 year, annualized)8.8%